Generic biologics are coming, but savings may not be dramatic

12/8/2011 | ScientificAmerican.com

By the end of this year, the FDA is set to issue a pathway for the approval of generic forms of biological drugs. However, even though the generic biologics, termed biosimilars, will cost less than brand-name biologics, keeping costs down won't be easy, because the manufacturing process of biologics is inherently more complicated than that of other pharmaceuticals. The FDA's biotechnology products office is hoping that the evolution of better analytical tools will make it easier for the agency to verify that biosimilars are structurally and functionally similar to their brand-name counterparts.

View Full Article in:

ScientificAmerican.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY